Pfizer (PFE) ended the recent trading session at $24.75, demonstrating a -1.2% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily loss of 0.19%.

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Arbutus Biopharma and Genevant Sciences have filed multiple patent infringement lawsuits against Pfizer and BioNTech over ...

After a tough stretch for shareholders over the last five years, with Pfizer stock down about 22% over that window, the ...

Pfizers approaching patent cliff and expanding pipeline remain central as the pharmaceutical group advances oncology programs ...

Pfizer is undervalued, trading just over 8x 2026 earnings, with improving dividend yield and core business fundamentals.

Eli Lilly & Company LLY and Pfizer PFE are large-cap U.S. drugmakers supported by broad product portfolios and strong research capabilities. Lilly has emerged as a leader in cardiometabolic medicine, ...

Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) both closed Q1 2026 with earnings beats, yet their post-report stories ...

Pfizer stock (NYSE: PFE) recently reported its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $17.8 billion and adjusted earnings of $0.63 per ...

In addition to J.P. Morgan, Pfizer also received a Hold from HSBC’s Rajesh Kumar in a report issued on July 6. However, on July 3, Jefferies maintained a Buy rating on Pfizer (NYSE: PFE).

Pfizer (NYSE:PFE) has faced significant challenges in recent years, with the stock losing half its value since late 2021 as COVID-19 vaccine demand waned. The pharmaceutical giant has struggled to ...

Pfizer stock (NYSE: PFE) recently reported its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $17.8 billion and adjusted earnings of $0.63 per ...